Stanniocalcin-1: New paradigms for cytoprotection and anti-inflammation

Stanniocalcin-1:细胞保护和抗炎的新范例

基本信息

项目摘要

Summary Reactive oxygen species (ROS), endothelial injury and macrophages play critical roles in ischemia/reperfusion (I/R) kidney injury. Our data show stanniocalcin-1 (STC1) diminishes superoxide generation in macrophages, through induction of uncoupling protein-2 (UCP2), decreases the response of macrophages to chemoattractants- and migration across an endothelial monolayer. In cultured endothelial cells, STC1 preserve barrier function. STC1: diminishes superoxide generation; inhibits cytokine-induced activation of Jun-N- terminal kinase (JNK) and loss of tight junction proteins expression. STC1 transgenic mice, which exhibit elevated serum levels and preferential expression of STC1 in macrophages and endothelium, display resistance to I/R kidney injury. Overall hypothesis: STC1 protects from I/R kidney injury through: suppression of superoxide generation; maintenance of normal endothelial barrier function following I/R kidney injury; and inhibition of macrophages. In Objective I, we will determine the role of superoxide and Daxx in STC1-mediated inhibition of JNK in endothelial cells. In Objective II, we will determine the effect of STC1 on hypoxia/reoxygenation (H/RO)-induced changes in the expression and assembly of tight junction proteins in cultured primary kidney endothelial cells. In the context of I/R kidney injury, Objective III will examine endothelial leakage to macromolecules, kidney inflammation and function after kidney endothelium-specific or macrophage-specific overexpression or deletion of STC1. Few therapeutic options are currently available for acute kidney injury (AKI). Our data identify STC1 as a potential therapeutic target for ischemic injury in the kidney and other organs, and our proposed studies will further elucidate STC1 mechanisms of action.
总结 活性氧(ROS)、内皮损伤和巨噬细胞在缺血/再灌注损伤中起重要作用 (I/R)肾损伤。我们的数据显示斯钙素-1(STC 1)减少了巨噬细胞中超氧化物的产生, 通过诱导解偶联蛋白-2(UCP 2),降低巨噬细胞对 化学引诱物-和穿过内皮单层的迁移。在培养的内皮细胞中,STC 1保留了 屏障功能STC 1:减少超氧化物生成;抑制胡萝卜素诱导的Jun-N- 末端激酶(JNK)和紧密连接蛋白表达丧失。STC 1转基因小鼠,其表现出 升高的血清水平和STC 1在巨噬细胞和内皮细胞中的优先表达,显示 抗I/R肾损伤。总体假设:STC 1通过以下方式保护I/R肾损伤:抑制 维持I/R肾损伤后正常的内皮屏障功能;以及 抑制巨噬细胞。在目的I中,我们将确定超氧化物和Daxx在STC 1介导的细胞凋亡中的作用。 内皮细胞中JNK的抑制。在目标II中,我们将确定STC 1对 缺氧/复氧(H/RO)诱导的紧密连接蛋白表达和组装的变化, 培养的原代肾内皮细胞。在I/R肾损伤的背景下,目标III将检查 大分子的内皮渗漏、肾脏炎症和肾内皮特异性或 巨噬细胞特异性过表达或缺失STC 1。目前几乎没有治疗选择可用于 急性肾损伤(阿基)。我们的数据确定STC 1作为缺血性损伤的潜在治疗靶点, 肾脏和其他器官,我们提出的研究将进一步阐明STC 1的作用机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID SHEIKH-HAMAD其他文献

DAVID SHEIKH-HAMAD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID SHEIKH-HAMAD', 18)}}的其他基金

Stanniocalcin-1: New paradigms for cytoprotection and anti-inflammation
Stanniocalcin-1:细胞保护和抗炎的新范例
  • 批准号:
    8824828
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Megalin, mitochondrial intracrine signaling and the kidney
巨蛋白、线粒体内分泌信号传导和肾脏
  • 批准号:
    10427148
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Stanniocalcin-1: New paradigms for cytoprotection and anti-inflammation
Stanniocalcin-1:细胞保护和抗炎的新范例
  • 批准号:
    9339510
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    7899903
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    8515390
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    8131592
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    8320393
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    7729602
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    7687670
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
NIH INTRAMURAL NRSA INSTITUTIONAL TRAINING PROGRAM
NIH 校内 NRSA 机构培训计划
  • 批准号:
    2213315
  • 财政年份:
    1993
  • 资助金额:
    --
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了